Pharmacology and similia principle: indirect secondary counter-regulation. Confirmation from in vitro experiments and classical provings
Keywords:primary and secondary action, receptors, disease origin, biophysical interactions
AbstractHomeopathy is universally known as an opponent of allopathic Medicine, namely scientific medicine based on ponderal drugs and recognised mechanisms of receptor agonism and antagonism following the dose-response curve. Over time the difficulty to explain with arguments the action of homeopathic ultra-diluted remedies has led many homeopaths to distance themselves from any pharmacological knowledges. Nevertheless this position fortgets not only the modalities in which homeopathy was born and has grown, but a lot of modern changes of view in body-mind communication, cell communication, neuro-immune-endocrinology and bioelectromagnetism, that could give new reasons to treat as clinical homeopathic practice is teaching and to recognize the principle of similars as a modern pharmacological principle. These arguments, receptorial cell communication, bioelectromagnetism and body-mind unity are the bases of Homeopathy and of the Similia Principle and are all included in embryonic but sufficiently clear considerations in the fundamental book of Hahnemann, the Organon (parr. 11, 13, 15-18, 21, 22, 29-32, 63-70). Two kind of evidences confirm the pharmacological bases of SimiliaPriniciple, in vitro experiments and homeopathic pathogenetic trials on healthy volunteers, best known as provings. Even clinical homeopathic phenomena like initial aggravation and return of old symptoms confirm this pharmacological view of the Simila Principle.
<a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><img alt="Creative Commons License" style="border-width:0" src="https://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png" /></a><br />This work is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/4.0/">Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License</a>.